LYSOGENE More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 31/12/08 | |
| Director of Finance/CFO | - | 31/12/19 | |
Marie Trad
CTO | Chief Tech/Sci/R&D Officer | - | 31/01/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Lichtlen
BRD | Director/Board Member | 56 | 31/03/18 |
Michel Picot
BRD | Director/Board Member | 72 | - |
| Chief Executive Officer | 52 | 31/12/08 |
LYSOGENE is a biotechnology company specializing in the research and development of gene therapies for the treatment of rare neurodegenerative diseases.
The company now has 2 drug candidates in clinical development of which 1 in phase 2/3 (LYS-SAF302 for the treatment of Sanfilippo syndrome type A) and 1 in phase 1/2 (LYS-GM101 for the treatment of GM1 gangliosidosis).
| 1st Jan change | Capi. | |
|---|---|---|
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| -29.81% | 1.48B | |
| +17.56% | 1.02B | |
| -4.37% | 733M | |
| -37.00% | 391M | |
| -46.94% | 383M |
